

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/815,481
				Filing Date	March 31, 2004
				First Named Inventor	Rajesh A. PATEL
				Art Unit	1618
				Examiner Name	E. Silverman
Sheet	1	of	1	Attorney Docket Number	304142000900

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	1.	US-4,670,014	06-02-1987	Hue et al.	

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)					
	2.	EP 0 153 896-A2,A3,B1		09-04-1985	Centre Technique du Cuir	Translation of Abstract Only.	
	3.	WO-03/101358-A1		12-11-2003	Titan Pharmaceuticals, Inc.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	4.	Anonymous. (Date Unknown). "NSAIDs Traditional NSAIDs," located at < http://www.arthritis.org/conditions/DrugGuide/Chart_nsaids.asp >, last visited on March 27, 2003, 4 pages.	
	5.	Anonymous. (December 14, 2002). "India Infoline Sector Reports Pharmaceuticals," located at < http://www.inidainfoline.com/sect/phfo/ch21.html >, last visited March 27, 2003, 2 pages.	
	6.	Bibbiani, F. et al. (Date Unknown). "Continuous Apomorphine Administration with Novel EVA Implants Reduces the Risks of Motor Complications Compared to Pulsatile Apomorphine in L-DOPA-Naïve, MPTP-Lesioned Primates," Abstract Preview: AAN3L_1225, located at < http://www.abstracts-on-line.com >, last visited on February 6, 2003, 1 page.	
	7.	DURING, M.J. et al. (April 1989). "Controlled Release of Dopamine from a Polymeric Brain Implant: In Vivo Characterization," <i>Ann. Neurol.</i> 25(4):351-356.	
	8.	HARDMAN, J.G. et al. eds. (2001). "Dopamine-Receptor Agonists," in <i>Goodman & Gilman's The Pharmacological Basis of Therapeutics</i> , Tenth Edition, McGraw-Hill: New York, NY, pp. 557-558.	
	9.	HARDMAN, J.G. et al. eds. (2001). "Levodopa," in <i>Goodman & Gilman's The Pharmacological Basis of Therapeutics</i> , Tenth Edition, McGraw-Hill: New York, NY, pp. 555-557.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.